Clinical trials: Myeloma, Plasma-Cell
Multiple Myeloma
Back Pain Prevention in Multiple Myeloma Using an External Spinal Brace
Consenting patients with multiple myeloma (MM) will be randomly allocated to receive either standard medical treatment (chemotherapy, radiotherapy, pain-killing medication) alone or standard medical treatment plus a brace.
- Trial name
- MAPP (NCT02898064)
- Testing
- thoracolumbosacral orthosis or cervicothoracolumbar orthosis, Standard care
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- University Hospitals of North Midlands NHS Trust
Healthy Volunteers, Relapsed Multiple Myeloma
A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
Part A: The purpose of Part A of this study is to evaluate the safety, pharmacokinetics, and pharmacodynamics of RO7875913 in healthy participants.
- Conditions
- Healthy Volunteers, Relapsed Multiple Myeloma, Refractory Multiple Myeloma
- Trial name
- NCT07342114
- Testing
- RO7875913, Cevostamab
- Where
- New Zealand
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Multiple Myeloma
APG-2575 Monotherapy or in Combination With Lenalidomide/DXMS in Subjects With Relapsed or Refractory Multiple Myeloma
This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy, and PK/ Pharmacodynamics of APG2575 monotherapy or in combination with lenalidomide (R) and dexamethasone (d) in patients with…
- Trial name
- NCT04674514
- Testing
- APG-2575, Rd
- Where
- 12 sites in China
- Volunteers
- 48 people
- Sponsor
- Ascentage Pharma Group Inc.
Anemia
A Study of Mircera in Anemic Patients With Multiple Myeloma
This study will investigate the efficacy, safety and pharmacokinetics of Mircera in adult anemic patients with multiple myeloma.
- Trial name
- NCT00360347
- Testing
- C.E.R.A.
- Where
- 5 sites in Czechia, Poland
- Sponsor
- Hoffmann-La Roche
Multiple Myeloma
Multiparametric Imaging in Multiple Myeloma
Patients with Multiple Myeloma will undergo single timepoint Positron Emission Tomography imaging with intravenously injected C11 Methionine to detect viable lesions.
- Trial name
- NCT02646085
- Testing
- C11 Methionine positron emission tomography
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Yingbing Wang
Cancer
Natural History Study of Fungal Infections of the Blood in Patients With Cancer or in Patients Who Have Undergone a Stem Cell Transplant
RATIONALE: Gathering information about how often fungal infections of the blood occur in patients with cancer or in patients who have undergone stem cell transplant may help doctors learn more about the disease.
- Trial name
- NCT00445952
- Testing
- clinical observation, management of therapy complications
- Where
- 5 sites in Belgium, France and 3 more
- Volunteers
- 304 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lymphoma, Multiple Myeloma
Evaluation of Influenza H1N1 Vaccine in Adults With Lymphoid Malignancies on Chemotherapy
The purpose of this study is to determine whether adults with hematologic malignancies on active systemic therapy or shortly after bone marrow transplantation need one or two doses of adjuvanted vaccine to achieve best possible…
- Conditions
- Lymphoma, Multiple Myeloma, Influenza A Virus, H1N1 Subtype
- Trial name
- NCT01016548
- Testing
- AS03-adjuvanted H1N1 pandemic influenza vaccine
- Where
- Canada
- Volunteers
- 42 people
- Sponsor
- University Health Network, Toronto
Multiple Myeloma, Auto Stem Cell Transplant
Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma
High dose chemotherapy with stem cell transplantation is commonplace in the treatment of multiple myeloma. This treatment uses a chemotherapy drug called Melphalan that has been used in several thousand bone marrow transplant…
- Trial name
- (Mel/MelVel) (NCT01241708)
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- Hackensack Meridian Health
Multiple Myeloma
UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission
There have been four previous Total Therapy (TT1 through IIIB) studies for multiple myeloma at the MIRT from 1989 to present. Results have shown that participants treated on these studies had better outcomes (meaning they have…
- Trial name
- NCT00869232
- Testing
- Velcade, Melphalan, Thalidomide
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- University of Arkansas
Refractory Multiple Myeloma
Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma
The study is designed as a multicenter, non-randomized, Phase II trial with one treatment arm. A total of 82 patients of both genders and older than 18 years with relapsed/refractory multiple myeloma are planned to be included in…
- Trial name
- NCT03731832
- Testing
- MLN9708, Pomalidomide 4 MG Oral Capsule, Dexamethasone
- Where
- 11 sites in Germany
- Volunteers
- 66 people
- Sponsor
- GWT-TUD GmbH
Multiple Myeloma (MM)
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019A in Patients With Relapsed/Refractory Multiple Myeloma.
This is a single-arm, open-label, single-center clinical trial to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of QI-019A in patients with relapsed/refractory multiple myeloma.
- Trial name
- NCT07429721
- Testing
- QI-019A Injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Multiple Myeloma
Finistere Myeloma Observatory (OMYFIN)
Current molecular risk stratification of multiple myeloma (MM), based on the presence of t(4 ;14) and 17p deletion, cannot fully explain treatment outcome heterogeneity, as other features also predict prognosis.
- Trial name
- OMYFIN (NCT06552221)
- Where
- France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Brest
Multiple Myeloma, Non-Hodgkin's Lymphoma
An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)
The primary purpose of this Phase I study is to evaluate the effect of the co-administration of CYP3A4 inducers on the pharmacokinetics profile of VELCADE (bortezomib).
- Trial name
- NCT00608907
- Testing
- bortezomib, bortezomib, rifampicin, bortezomib, dexamethasone
- Where
- 9 sites in Israel, Italy and 3 more
- Volunteers
- 61 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Myeloma
Non-invasive MRD Assessment in Multiple Myeloma
The purpose of this study is to investigate the sensitivity and accuracy of non-invasive MRD assessment using liquid biopsy (blood draw) and functional imaging (whole body MRI) in participants with new diagnosed and previously…
- Trial name
- NIRVANA (NCT05625971)
- Testing
- MRD Assessment
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Rajshekhar Chakraborty, MD
Hematologic Neoplasm, Acute Leukemia
PENELOPE Observational Study: Prophylaxis and Treatment of Arterial and Venous Thromboembolism
The primary objective of the study is to assess efficacy and safety of different prophylactic or therapeutic antithrombotic approaches in patients with hematologic neoplasms and platelet count <50 x109/L, including unfractionated…
- Conditions
- Hematologic Neoplasm, Acute Leukemia, Myelodysplastic Syndrome, Lymphoma
- Trial name
- NCT01855698
- Testing
- Observation
- Where
- 23 sites in Italy
- Volunteers
- 99 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Lymphoma, Refractory B-Cell Lymphoma
Study of CAR-T Therapy in Older Patients
This study is being done to find out how older patients respond to CAR-T cell therapy and how the treatment affects their quality of life.
- Conditions
- Lymphoma, Refractory B-Cell Lymphoma, Lymphoma, B-Cell, DLBCL NOS
- Trial name
- NCT04300998
- Testing
- Activities of Daily Living/ADLs, Instrumental Activity of Daily Living, Timed Up and Go
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT)
The goal of this study is to gain new knowledge about genetic risk factors thta may affect the development of mucositis, the chemotherapy-induced sores in the mouth and esophagus following HSCT.
- Conditions
- Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Multiple Myeloma
- Trial name
- NCT01402687
- Where
- United States
- Volunteers
- 181 people
- Sponsor
- Dana-Farber Cancer Institute
Lymphoma, Non-Hodgkin, Multiple Myeloma
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available.
- Conditions
- Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
- Trial name
- CAPTUR (NCT03297606)
- Testing
- Olaparib, Dasatinib, Nivolumab plus Ipilimumab
- Where
- 10 sites in Canada
- Volunteers
- 720 people
- Sponsor
- Canadian Cancer Trials Group
Refractory Multiple Myeloma
Filgrastim With or Without Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide
This clinical trial studies filgrastim (G-CSF) with or without plerixafor in treating patients with multiple myeloma (MM) previously treated with lenalidomide.
- Trial name
- NCT01301963
- Testing
- plerixafor, filgrastim
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Case Comprehensive Cancer Center
Multiple Myeloma
GMMG-HD11/DSMM XXI/64007957MMY3010
This is an open-label, randomized interventional multicenter Phase 3 clinical trial to investigate the efficacy and safety of Tec-DRd induction therapy and fixed-duration Tec-D maintenance post ASCT in adult participants with TE…
- Trial name
- AugMMent (NCT07671287)
- Testing
- Teclistamab, Daratumumab, Lenalidomide
- Volunteers
- 399 people
- Sponsor
- University of Heidelberg Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.